[go: up one dir, main page]

WO2004103317A3 - Transdermal buprenorphine dosage regimen for treatment of diarrhea - Google Patents

Transdermal buprenorphine dosage regimen for treatment of diarrhea Download PDF

Info

Publication number
WO2004103317A3
WO2004103317A3 PCT/US2004/009335 US2004009335W WO2004103317A3 WO 2004103317 A3 WO2004103317 A3 WO 2004103317A3 US 2004009335 W US2004009335 W US 2004009335W WO 2004103317 A3 WO2004103317 A3 WO 2004103317A3
Authority
WO
WIPO (PCT)
Prior art keywords
diarrhea
dosage regimen
symptoms
treatment
transdermal buprenorphine
Prior art date
Application number
PCT/US2004/009335
Other languages
French (fr)
Other versions
WO2004103317A2 (en
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Bruce E Reidenberg
Daniel A Spyker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa, Bruce E Reidenberg, Daniel A Spyker filed Critical Euro Celtique Sa
Publication of WO2004103317A2 publication Critical patent/WO2004103317A2/en
Publication of WO2004103317A3 publication Critical patent/WO2004103317A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A buprenorphine transdermal dosage regimen is provided that reduces symptoms such as pain and/or diarrhea are effectively reduced in patients suffering from one or more gastrointestinal conditions. The dosage regimen reduces the severity of breakthrough symptoms in a patient treated for symptoms of diarrhea. The gastrointestinal conditions include irritable bowel syndrome (IBS), short gut syndrome, microscopic colitis, and diarrhea associated with VIP-secreting carcinoids.
PCT/US2004/009335 2003-05-15 2004-03-26 Transdermal buprenorphine dosage regimen for treatment of diarrhea WO2004103317A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47148003P 2003-05-15 2003-05-15
US60/471,480 2003-05-15

Publications (2)

Publication Number Publication Date
WO2004103317A2 WO2004103317A2 (en) 2004-12-02
WO2004103317A3 true WO2004103317A3 (en) 2005-03-10

Family

ID=33476852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009335 WO2004103317A2 (en) 2003-05-15 2004-03-26 Transdermal buprenorphine dosage regimen for treatment of diarrhea

Country Status (1)

Country Link
WO (1) WO2004103317A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41489E1 (en) 1997-02-24 2010-08-10 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
JP5054893B2 (en) * 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． Transdermal buprenorphine for analgesia
ATE375149T1 (en) 2003-07-25 2007-10-15 Euro Celtique Sa TREATMENT OF WITHDRAWAL
SMT201800073T1 (en) * 2014-04-28 2018-03-08 Orphomed Inc Buprenorphine dimer and its use in treatment of gastrointestinal disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6306876B1 (en) * 1999-12-22 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6306876B1 (en) * 1999-12-22 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41489E1 (en) 1997-02-24 2010-08-10 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
USRE41571E1 (en) 1997-02-24 2010-08-24 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine

Also Published As

Publication number Publication date
WO2004103317A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007100763A3 (en) Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
WO2007130892A3 (en) Method for treatment of constipation-predominant irritable bowel syndrome
Perri et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection
PT1485078E (en) Milnacipran for the treatment of irritable bowel syndrome
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
EP1680166A4 (en) Methods and apparatus for heart failure treatment
EP1377380A4 (en) Apparatus for treating waste, particularly medical waste, to facilitate its disposition
CY1108921T1 (en) CLEANING USES FOR THE TREATMENT OF INFECTIOUS INTEREST SYNDROME
WO2005082504A3 (en) Plasma detoxification system and methods of use
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
EP2192901A4 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
IL185998A0 (en) Methods for diagnosis and treatment of processing difficulties, integration problems, imbalances and abnormal postures
AU2002368399A1 (en) Integrated plasma-frequency induction process for waste treatment, resource recovery and apparatus for realizing same
WO2006031980A3 (en) Treatment for cancer-related fatigue
IL160754A0 (en) Dosage form, device and methods of treatment
WO2004103317A3 (en) Transdermal buprenorphine dosage regimen for treatment of diarrhea
AU2003286726A8 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
IL175579A0 (en) Epithelium treatment methods and devices for treating the epithelium
WO2008067351A3 (en) Method of diagnosing and treating glioma
WO2008063853A3 (en) Cancer treatment method
WO2002036124A3 (en) Treatment and method using loratadine and montelukast
WO2007118077A3 (en) Mycobacterial catalase-peroxidase in the diagnosis and treatment of sarcoidosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase